Bevacizumab

Bevacizumab · Anti-VEGF monoclonal antibody

Metastatic colorectal cancer, advanced NSCLC, recurrent glioblastoma, hepatocellular carcinoma and other solid tumors

100mg/400mg IV infusion Every 2-3 weeks

Therapeutic Areas

Oncology

Marketed Products

Bevacizumab

Modality

Bevacizumab

Core Products

Osimertinib · 3rd-generation EGFR TKI

Palbociclib · CDK4/6 inhibitor

Rituximab · Anti-CD20 monoclonal antibody

Creating a Healthier Future Together

Explore our innovative products and pipeline, and see how Poseidon brings hope to patients worldwide